Physician profile
An N Lam
NPI 1457826067
$3,791.01
in general payments reported to CMS, 2019-2025
24 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $83.93 · 2023: $948 · 2024: $1,608 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.81 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $717.15 | 2023-2025 | Farxiga, Lokelma |
| Amgen INC. | $475.51 | 2023-2025 | Tavneos, Parsabiv, Aranesp |
| Fresenius USA Marketing, INC. | $284.98 | 2023-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $271.79 | 2023-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $264.66 | 2023-2025 | |
| Nxstage Medical, INC. | $251.09 | 2023-2025 | Nxstage System One |
| Opko Pharmaceuticals, LLC | $197.55 | 2022-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $197.39 | 2024-2025 | Terlivaz, Acthar |
| Vifor Pharma, INC. | $186.95 | 2022-2025 | Veltassa |
| Akebia Therapeutics INC | $145.94 | 2023-2025 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $113.47 | 2022-2024 | |
| Inspire Medical Systems, INC. | $97.17 | 2024 | Inspire |
| Cormedix INC. | $83.42 | 2024 | Defencath |
| Alexion Pharmaceuticals, INC. | $63.60 | 2024 | Ultomiris |
| Aurinia Pharma U.S., INC. | $56.43 | 2024 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $55.83 | 2023-2025 | Filspari |
| Ani Pharmaceuticals, INC. | $54.73 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.33 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $48.60 | 2025 | Ozempic, Rybelsus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $47.70 | 2025 | Voyxact |
| Invivyd INC | $44.76 | 2025 | Pemgarda |
| Calliditas Therapeutics US INC. | $41.24 | 2025 | Tarpeyo |
| Pharmacosmos Therapeutics INC. | $22.74 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.98 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw An Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.